Parsabiv
(etelcalcetide) injection for intravenous use
All edits
Edits on 7 Apr, 2022
Vitalii Mazuryk
Edits made to:
Description (+45 characters)
Article (+348 characters)
Parsabiv
(etelcalcetide) injection for intravenous use
Article
Parsabiv® (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Parsabiv® has not been studied in adult patients with parathyroid cancer, primary hyperparathyroidism, or with CKD who are not on hemodialysis and should not be used in these patients.
Vitalii Mazuryk
Edits made to:
Infobox (+2 properties)
Infobox
Industry
Product parent company
Vitalii Mazuryk
Edits made to:
Infobox (+2 properties)
Parsabiv
(etelcalcetide) injection for intravenous use
Infobox
Is a
Website
Find more entities like Parsabiv
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.